Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jan;86(1):e15-e17.
doi: 10.1016/j.jinf.2022.08.021. Epub 2022 Aug 27.

The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: A systematic review with meta-analysis

Yong Wang  1 , Jun Zheng  2 , Kongfu Zhu  3 , Chengshi Xu  4 , Daping Wang  3 , Mengzhuo Hou  5
Affiliations
Meta-Analysis

The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: A systematic review with meta-analysis

Yong Wang et al. J Infect. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no competing interest

Figures

Fig1 A
Fig.1. A
Association between tixagevimab-cilgavimab treatment and mortality. B Association between tixagevimab-cilgavimab treatment and serious adevents. C Association between tixagevimab-cilgavimab treatment and COVID-19 infection.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Vellas C, Kamar N, Izopet J. Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment. J Infect. 2022 Jul 22 doi: 10.1016/j.jinf.2022.07.014. S0163-4453(22)00422-4. doi: - DOI - PMC - PubMed
    1. Keam SJ. Tixagevimab + cilgavimab: first approval. Drugs. 2022 Jun 21:1–10. doi: 10.1007/s40265-022-01731-1. - DOI - PMC - PubMed
    1. Yinong Young-Xu, Lauren Epstein, Vincent C Marconi, et al. Tixagevimab/Cilgavimab for prevention of COVID-19 during the omicron surge: retrospective analysis of national VA electronic data medRxiv2022.05.28.22275716; doi:https://doi.org/10.1101/2022.05.28.22275716 - PMC - PubMed
    1. Holland Thomas L, Ginde Adit A, Paredes Roger, et al. Tixagevimab/Cilgavimab for treatment of hospitalised COVID-19 patients: a randomised, double-blind, Phase 3 Trial. Available at SSRN: https://doi.org/10.2139/ssrn.4087355 - PMC - PubMed
    1. Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022 Jun 7 doi: 10.1016/S2213-2600(22)00180-1. S2213-2600(22)00180-1. - DOI - PMC - PubMed